282 related articles for article (PubMed ID: 28008779)
21. Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer.
Moy B; Tu D; Pater JL; Ingle JN; Shepherd LE; Whelan TJ; Goss PE
Ann Oncol; 2006 Nov; 17(11):1637-43. PubMed ID: 16936184
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.
Munzone E; Giobbie-Hurder A; Gusterson BA; Mallon E; Viale G; Thürlimann B; Ejlertsen B; MacGrogan G; Bibeau F; Lelkaitis G; Price KN; Gelber RD; Coates AS; Goldhirsch A; Colleoni M;
Ann Oncol; 2015 Dec; 26(12):2442-9. PubMed ID: 26387144
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial.
Dowsett M; Cuzick J; Howell A; Jackson I;
Br J Cancer; 2001 Aug; 85(3):317-24. PubMed ID: 11487258
[TBL] [Abstract][Full Text] [Related]
24. Letrozole: a review of its use in the treatment of postmenopausal women with hormone-responsive early breast cancer.
Keating GM
Drugs; 2009 Aug; 69(12):1681-705. PubMed ID: 19678717
[TBL] [Abstract][Full Text] [Related]
25. Third-generation aromatase inhibitors in the treatment of advanced breast cancer.
Nabholtz JM; Reese DM
Breast Cancer; 2001; 8(4):305-9. PubMed ID: 11791122
[No Abstract] [Full Text] [Related]
26. A preliminary study on the association of tamoxifen, endoxifen, and 4-hydroxytamoxifen with blood lipids in patients with breast cancer.
Siqueira MLS; Andrade SMV; Vieira JLF; Monteiro MC
Biomed Pharmacother; 2021 Oct; 142():111972. PubMed ID: 34391185
[TBL] [Abstract][Full Text] [Related]
27. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
28. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).
Gershanovich M; Chaudri HA; Campos D; Lurie H; Bonaventura A; Jeffrey M; Buzzi F; Bodrogi I; Ludwig H; Reichardt P; O'Higgins N; Romieu G; Friederich P; Lassus M
Ann Oncol; 1998 Jun; 9(6):639-45. PubMed ID: 9681078
[TBL] [Abstract][Full Text] [Related]
29. Method to test whether late extended letrozole, rather than self- selection, improves the outcome in patients with breast cancer who have completed 5 years of tamoxifen.
Vaidya JS
J Clin Oncol; 2008 Jul; 26(19):3291; author reply 3291. PubMed ID: 18591569
[No Abstract] [Full Text] [Related]
30. Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer.
Hutson PR; Love RR; Havighurst TC; Rogers E; Cleary JF
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8722-7. PubMed ID: 16361559
[TBL] [Abstract][Full Text] [Related]
31. Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and letrozole in human plasma and its application to a clinical study.
Beer B; Schubert B; Oberguggenberger A; Meraner V; Hubalek M; Oberacher H
Anal Bioanal Chem; 2010 Oct; 398(4):1791-800. PubMed ID: 20730580
[TBL] [Abstract][Full Text] [Related]
32. Tamoxifen therapy for patients with breast cancer - Authors' reply.
Davies C; Gray R; Pan H; Peto R;
Lancet; 2013 Jun; 381(9883):2078-9. PubMed ID: 23769225
[No Abstract] [Full Text] [Related]
33. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
34. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Stearns V; Johnson MD; Rae JM; Morocho A; Novielli A; Bhargava P; Hayes DF; Desta Z; Flockhart DA
J Natl Cancer Inst; 2003 Dec; 95(23):1758-64. PubMed ID: 14652237
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
Mouridsen H; Keshaviah A; Coates AS; Rabaglio M; Castiglione-Gertsch M; Sun Z; Thürlimann B; Mauriac L; Forbes JF; Paridaens R; Gelber RD; Colleoni M; Smith I; Price KN; Goldhirsch A
J Clin Oncol; 2007 Dec; 25(36):5715-22. PubMed ID: 17998546
[TBL] [Abstract][Full Text] [Related]
36. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial.
Phillips KA; Ribi K; Sun Z; Stephens A; Thompson A; Harvey V; Thürlimann B; Cardoso F; Pagani O; Coates AS; Goldhirsch A; Price KN; Gelber RD; Bernhard J
Breast; 2010 Oct; 19(5):388-95. PubMed ID: 20385495
[TBL] [Abstract][Full Text] [Related]
37. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
Kaufmann M; Rody A
Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
[TBL] [Abstract][Full Text] [Related]
38. Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study.
Masuda N; Nishimura R; Takahashi M; Inoue K; Ohno S; Iwata H; Mori Y; Hashigaki S; Muramatsu Y; Nagasawa T; Umeyama Y; Toi M
Cancer Sci; 2018 Mar; 109(3):803-813. PubMed ID: 29345736
[TBL] [Abstract][Full Text] [Related]
39. Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial.
Zdenkowski N; Forbes JF; Boyle FM; Kannourakis G; Gill PG; Bayliss E; Saunders C; Della-Fiorentina S; Kling N; Campbell I; Mann GB; Coates AS; Gebski V; Davies L; Thornton R; Reaby L; Cuzick J; Green M;
Ann Oncol; 2016 May; 27(5):806-12. PubMed ID: 26861603
[TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women.
Tanii H; Shitara Y; Horie T
Eur J Clin Pharmacol; 2011 Oct; 67(10):1017-25. PubMed ID: 21494765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
